U.S. COURT OF APPEALS CONFIRMS THE VALIDITY RCT’S PATENT COVERING VIMPAT® (LACOSAMIDE)
UCB announces today that in a decision released today, the Court of Appeals for the Federal Circuit (CAFC) has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551 related to Vimpat® (lacosamide), UCB’s anti-epileptic drug.
“We are pleased with the CAFC decision,” said Anna Richo UCB’s Executive Vice President and General Counsel. “This confirms the strength of our intellectual property for Vimpat® and maintains UCB’s exclusivity position until March 2022.” This decision supports UCB’s commitment to epilepsy patients and UCB’s ability to deliver Vimpat® to patients.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With approximately 7500 people operating in 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news